Skip to main content
Back
MSMKF logo

MatsukiyoCocokara & Co.

Data quality: 100%
Overbought
MSMKF
OTC Healthcare Medical - Pharmaceuticals
$18.17
$0.00 (0.00%)
Mkt Cap: 7.23B
Day Range
$18.17 $20.43
52-Week Range
$14.09 $21.22
Volume
24
50D / 200D Avg
$18.17 / $19.03
Prev Close
$18.17

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 0.1 0.4
P/B 0.0 2.9
ROE % 10.6 3.8
Net Margin % 5.2 3.9
Rev Growth 5Y % 17.5 10.0
D/E 0.0 0.2

Key Takeaways

Revenue grew 17.50% annually over 5 years — strong growth
ROE of 10.56% — decent returns on equity
Debt/Equity of 0.00 — conservative balance sheet
Generating 67.01B in free cash flow
P/E of 0.13 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 13.68%

Growth

Revenue Growth (5Y)
17.50%
Revenue (1Y)3.82%
Earnings (1Y)4.45%
FCF Growth (3Y)19.01%

Quality

Return on Equity
10.56%
ROIC11.77%
Net Margin5.15%
Op. Margin7.73%

Safety

Debt / Equity
0.00
Current Ratio2.24
Interest Coverage1282.53

Valuation

P/E Ratio
0.13
P/B Ratio0.01
EV/EBITDA-1.25
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3.82% Revenue Growth (3Y) 5.64%
Earnings Growth (1Y) 4.45% Earnings Growth (3Y) 16.13%
Revenue Growth (5Y) 17.50% Earnings Growth (5Y) 26.13%
Profitability
Revenue (TTM) 1.06T Net Income (TTM) 54.68B
ROE 10.56% ROA 7.67%
Gross Margin 35.06% Operating Margin 7.73%
Net Margin 5.15% Free Cash Flow (TTM) 67.01B
ROIC 11.77% FCF Growth (3Y) 19.01%
Safety
Debt / Equity 0.00 Current Ratio 2.24
Interest Coverage 1282.53 Dividend Yield 0.02%
Valuation
P/E Ratio 0.13 P/B Ratio 0.01
P/S Ratio 0.01 PEG Ratio 2.32
EV/EBITDA -1.25 Dividend Yield 0.02%
Market Cap 7.23B Enterprise Value -102.31B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.06T 1.02T 951.25B 729.97B 556.91B
Net Income 54.68B 52.35B 40.55B 34.38B 21.60B
EPS (Diluted) 133.81 125.27 95.99 93.78 70.12
Gross Profit 372.24B 331.80B 329.32B 240.30B 182.10B
Operating Income 82.08B 75.71B 62.28B 41.41B 31.53B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 712.78B 724.75B 688.13B 656.74B 368.92B
Total Liabilities 191.28B 209.57B 205.42B 192.40B 122.46B
Shareholders' Equity 520.80B 514.73B 482.47B 464.32B 246.46B
Total Debt 2.21B 20.66B 21.41B 22.92B 23.70B
Cash & Equivalents 111.75B 117.72B 95.22B 74.52B 38.52B
Current Assets 364.32B 370.80B 329.81B 304.39B 175.70B
Current Liabilities 162.64B 179.43B 153.27B 142.45B 84.89B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#582 of 820
34
Value Defensive Investing (Benjamin Graham)
#682 of 708
2

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026